Drugs / 4D-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04483440 | Jun 2020 → May 2027 expected | choroideremia | 4D Molecular Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-10-25 | 4D Molecular Therapeutics | Results 4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia 4dmoleculartherapeutics.com ↗
4D-110 was generally well-tolerated, with initial evidence of clinical activity observed |
| 2021-06-24 | 4D Molecular Therapeutics | Results 4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License 4dmoleculartherapeutics.com ↗
Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that 4D-110 was well-tolerated and did not result in any dose-limiting toxicity (n=6; all patients followed between one and nine months) |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4D-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04483440 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus (AAV) gene therapy” NCT04483440 ↗ |
| Route | Intravitreal | “single intravitreal (IVT) injection” NCT04483440 ↗ |
| Target | CHM | “transgene encoding a codon-optimized human CHM gene” NCT04483440 ↗ |